Litigation Details for Board of Regents, The University of Texas System v. Boston Scientific Corporation (D. Del. 2018)

Board of Regents, The University of Texas System v. Boston Scientific Corporation (D. Del. 2018)

Docket	1:18-cv-00392	Date Filed	2018-03-13
Court	District Court, D. Delaware	Date Terminated	2024-06-28
Cause	35:271 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	Plaintiff	Referred To
Patents	12,005,062
Link to Docket	External link to docket

Details for Board of Regents, The University of Texas System v. Boston Scientific Corporation (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-03-13				External link to document

Board of Regents v. Boston Scientific: Patent Litigation Summary and Analysis, 1:18-cv-00392

Last updated: August 3, 2026

Board of Regents, The University of Texas System v. Boston Scientific Corporation, No. 1:18-cv-00392, was a patent dispute involving drug-eluting stent technology and methods for treating vascular conditions. The Federal Circuit’s principal ruling addressed patent eligibility under 35 U.S.C. § 101. It held that the asserted method claims were directed to a patent-eligible application of a treatment approach rather than an unpatentable natural law, reversing the district court’s dismissal and remanding the case for further proceedings. Board of Regents of the University of Texas System v. Boston Scientific Corp., 935 F.3d 1367 (Fed. Cir. 2019).

The case was a medical-device patent dispute, not a pharmaceutical Orange Book case. Generic-drug, biosimilar, and Hatch-Waxman Paragraph IV issues were not central to the litigation.

What patents and technology were at issue in Board of Regents v. Boston Scientific?

The dispute concerned University of Texas intellectual property covering the use of drug-eluting stents to treat vascular conditions, including restenosis. The technology generally combines:

• A vascular stent implanted in a patient;
• A therapeutic agent delivered from or associated with the stent; and
• A treatment protocol intended to reduce or prevent abnormal re-narrowing of a blood vessel.

Boston Scientific marketed drug-eluting stent systems that used polymer coatings and antiproliferative drugs. The University alleged that Boston Scientific’s products and related treatment methods practiced claims covering this technology.

The Federal Circuit analyzed the asserted claims as method-of-treatment claims. The court did not treat the claims as merely claiming the biological relationship between a drug and restenosis. Instead, it evaluated the claims as requiring a concrete clinical intervention involving implantation of a stent and use of a therapeutic agent.

The publicly reported Federal Circuit decision is the controlling appellate authority for the § 101 issue. It does not provide a basis for assigning the entire University patent portfolio to Boston Scientific’s products or for treating every drug-eluting stent as infringing.

What was the procedural history of case 1:18-cv-00392?

Date	Event	Significance
2018	University of Texas filed the action in the Western District of Texas	Initiated the patent infringement dispute against Boston Scientific
2018-2019	Boston Scientific challenged the asserted claims under § 101	The challenge sought dismissal before a full infringement and validity trial
2019	District court dismissed the action under § 101	The case was terminated at the pleading stage based on patent-ineligibility reasoning
Aug. 16, 2019	Federal Circuit issued its decision	The appellate court reversed the § 101 dismissal
After Aug. 2019	Case remanded to the district court	Infringement, claim construction, anticipation, obviousness, written description, and damages issues remained for further proceedings

The key appellate decision is reported at 935 F.3d 1367. The Federal Circuit’s reversal removed the early eligibility barrier. It did not establish infringement, validity under §§ 102 or 103, damages, or a right to an injunction.

Why did the Federal Circuit reverse the § 101 dismissal?

The Federal Circuit applied the two-step framework from Alice Corp. v. CLS Bank International, 573 U.S. 208 (2014), and Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. 66 (2012).

Step one: Was the claim directed to a natural law?

The court treated the claims as directed to a specific treatment method using a drug-eluting stent. The claims did not merely state that a therapeutic agent affects restenosis. They required a treatment action involving a stent and a patient.

That distinction was material. A claim that simply identifies a biological correlation can be vulnerable under § 101. A claim that applies a treatment protocol to a patient may be eligible when the protocol requires a specific intervention.

Step two: Did the claim contain an inventive concept?

Because the claims were not directed solely to a natural law, the Federal Circuit did not need to treat conventional implementation steps as the entire substance of the invention. The claimed combination of stent implantation and drug delivery supplied a practical application of the treatment concept.

The court distinguished cases in which a patent merely instructs a physician to observe a natural relationship or apply routine laboratory steps. The University claims required a treatment using a particular medical device configuration and therapeutic approach.

Business impact of the holding

The decision narrowed the value of an early § 101 motion as a defense to method-of-treatment claims involving drug-eluting stents. Boston Scientific still could challenge the patent on other grounds, including:

• Anticipation under § 102;
• Obviousness under § 103;
• Lack of written description under § 112;
• Lack of enablement under § 112;
• Noninfringement;
• Claim construction; and
• Limitations on damages or standing.

The Federal Circuit ruling therefore preserved the University’s ability to pursue the case but did not determine ultimate liability.

What patent litigation issues remained after the Federal Circuit decision?

After remand, the central disputes would have shifted from threshold eligibility to conventional patent litigation questions.

Infringement

The University would need to prove that Boston Scientific’s accused stent products or associated treatment methods met every limitation of at least one asserted claim, either literally or under the doctrine of equivalents.

Likely factual issues included:

• The structure and composition of the stent coating;
• The identity and release characteristics of the therapeutic agent;
• Whether the product instructions encouraged performance of the claimed treatment method;
• Whether physicians directly practiced the asserted method;
• Whether Boston Scientific induced infringement under § 271(b); and
• Whether product sales constituted contributory infringement under § 271(c).

Method claims can create additional proof challenges because the patent owner must connect product use to the claimed treatment steps.

Claim construction

Claim construction would determine the scope of terms relating to:

• Drug-eluting stents;
• Therapeutic agents;
• Vascular conditions;
• Treatment of restenosis;
• Implantation location; and
• Drug release or coating characteristics.

A narrow construction could materially reduce the number of accused products. A broad construction could increase exposure but create stronger invalidity arguments.

Prior art and obviousness

Drug-eluting stents were a mature technology by the time of the lawsuit. Boston Scientific could therefore be expected to examine:

• Earlier stent patents;
• Clinical publications;
• Prior disclosures involving antiproliferative drugs;
• Earlier drug-coated vascular devices;
• Combination references involving stents and therapeutic agents; and
• Public use or sale evidence.

The University’s strongest validity position would depend on claim limitations that were not routine in the prior art, such as a particular treatment indication, drug-delivery profile, stent configuration, or clinical sequence.

How strong was the University of Texas patent position?

The Federal Circuit ruling gave the University a favorable position on patent eligibility, but § 101 was only one part of the validity analysis.

Issue	Assessment
Patent eligibility	Strong after the Federal Circuit reversal
Infringement	Dependent on product structure, labeling, use instructions, and claim scope
Novelty	Dependent on the specific asserted claim limitations and prior art
Obviousness	Material risk because drug-eluting stents were established technology
Written description	Potential issue if the claims broadly covered drug, device, and treatment combinations not fully disclosed
Enablement	Dependent on the breadth of the claims and supporting technical disclosure
Damages	Dependent on patent term, product sales, apportionment, and royalty methodology
Injunction	Uncertain; medical-device licensing economics and the eBay factors would control

The strongest legal asset was the appellate rejection of a categorical eligibility theory. The principal commercial risk remained whether the claims were sufficiently narrow to distinguish the prior art but sufficiently broad to cover Boston Scientific’s products.

Did Boston Scientific file a Paragraph IV challenge?

No. Paragraph IV is a Hatch-Waxman mechanism used by generic-drug applicants to challenge patents listed in the FDA Orange Book for an approved drug.

This case involved medical-device and drug-eluting stent technology. It was not an abbreviated new drug application dispute. Boston Scientific’s defenses arose in ordinary patent litigation under the Patent Act rather than through a Paragraph IV certification.

What was the FDA and Orange Book status?

The case did not concern an Orange Book-listed pharmaceutical product.

Regulatory issue	Status
FDA drug approval	Not the basis of the dispute
FDA biologics approval	Not applicable
Orange Book listing	Not applicable to the asserted device technology
Hatch-Waxman exclusivity	Not applicable
Paragraph IV certification	Not applicable
Medical-device clearance or approval	Relevant to commercial products, but separate from patent validity
Biosimilar pathway	Not applicable

Drug-eluting stents may combine a medical device with a drug component, but that does not convert the underlying patent case into an Orange Book proceeding. Regulatory clearance or approval also does not establish patent infringement or validity.

Did the case involve biosimilar risk or generic-entry risk?

Biosimilar risk was not relevant because Boston Scientific was not challenging a biologic reference product. Traditional generic-entry risk also was not the correct framework.

The commercial threat was device competition. A successful University patent claim could affect:

• Boston Scientific’s ability to sell covered stent platforms;
• Future product development using similar coating or delivery technology;
• Licensing negotiations with stent manufacturers;
• Hospital purchasing and contracting;
• Royalty exposure on covered sales; and
• Design-around strategies involving drug, polymer, coating, or delivery changes.

Any launch analysis would need to focus on patent term, claim scope, product-specific infringement, regulatory requirements, and competing patent estates.

Which companies and products were commercially relevant?

Boston Scientific was the defendant and a major manufacturer of interventional cardiology products, including drug-eluting stents. The broader competitive landscape included companies such as Abbott, Medtronic, and other cardiovascular-device manufacturers.

The case potentially affected products using:

• Drug-eluting stent platforms;
• Polymer-based drug coatings;
• Antiproliferative agents;
• Controlled drug release; and
• Treatment protocols for restenosis and related vascular conditions.

The Federal Circuit decision did not hold that all competing stent products infringed. It only established that the asserted claim category could survive a § 101 dismissal.

Did the parties settle or enter a licensing agreement?

The Federal Circuit decision does not report a settlement, license, royalty agreement, or covenant not to sue. It records the reversal of the district court’s eligibility dismissal and remand for further proceedings.

A settlement would ordinarily resolve the case without a merits determination on infringement, validity, or damages. Because the appellate ruling did not impose a royalty or injunction, it should not be treated as evidence of a license or commercial settlement.

What patent expiration and exclusivity issues applied?

Patent expiration must be determined patent by patent from the asserted patent numbers, filing history, priority claims, patent-term adjustments, patent-term extensions, and terminal disclaimers. The reported Federal Circuit opinion is sufficient to establish the § 101 ruling, but it does not establish a single expiration date for every University patent potentially relevant to drug-eluting stents.

The case also did not involve FDA marketing exclusivity. The relevant exclusivity would have been patent exclusivity under Title 35, subject to:

• The patent’s effective filing date;
• The 20-year patent term;
• Patent-term adjustment;
• Patent-term extension, if available;
• Terminal disclaimers;
• Claim survival after reexamination or post-grant review; and
• Any later disclaimer or expiration event.

What litigation and licensing risks did the decision create?

For Boston Scientific, the reversal increased litigation cost and delayed resolution. The company could no longer dispose of the case through § 101 alone. It would need to litigate claim scope, prior art, infringement, and damages.

For the University, the decision improved leverage in licensing discussions but did not guarantee a payment. The University still had to prove a viable infringement theory and defend the claims against prior-art and § 112 challenges.

For other device manufacturers, the decision increased diligence risk when evaluating drug-eluting stent technologies. A company designing around the claims would likely examine:

• Alternative coating materials;
• Different therapeutic agents;
• Modified drug-release profiles;
• Distinct stent architectures;
• Different treatment indications; and
• Product labeling that avoids directing the claimed method.

Key Takeaways

• The dispute involved University of Texas patent rights relating to drug-eluting stents and vascular treatment methods.
• The Federal Circuit reversed the district court’s § 101 dismissal in 2019.
• The asserted method claims were treated as a specific medical treatment application, not merely a claim to a natural biological relationship.
• The appellate ruling did not establish infringement, patent validity under §§ 102, 103, or 112, damages, or an injunction.
• The case was not an Orange Book, Hatch-Waxman, Paragraph IV, generic-drug, or biosimilar dispute.
• Commercial exposure depended on the scope of the asserted claims and their application to Boston Scientific’s specific stent products.
• The main post-remand risks were claim construction, obviousness, written description, enablement, noninfringement, and damages.
• The reported appellate decision does not identify a settlement, license, royalty award, or final merits judgment.

FAQs About Board of Regents v. Boston Scientific

What did the Federal Circuit decide in Board of Regents v. Boston Scientific?

The Federal Circuit reversed dismissal under § 101 and held that the asserted method claims were directed to a patent-eligible treatment application involving drug-eluting stent technology.

Was Boston Scientific found to infringe University of Texas patents?

No. The reported Federal Circuit decision resolved patent eligibility, not infringement. Infringement required further proceedings after remand.

Was the case related to Boston Scientific’s coronary stent products?

Yes. The litigation concerned drug-eluting stent technology and associated vascular treatment methods. The appellate decision did not identify every affected Boston Scientific product or hold that all drug-eluting stents infringed.

Did the University of Texas obtain an injunction against Boston Scientific?

No injunction was awarded in the Federal Circuit decision. The court reversed the dismissal and remanded the case.

Is Board of Regents v. Boston Scientific relevant to pharmaceutical patent litigation?

Yes, but mainly for its § 101 analysis of method-of-treatment claims. It is not an Orange Book or Hatch-Waxman precedent concerning generic drug entry.

References

1. Alice Corp. Pty. Ltd. v. CLS Bank International, 573 U.S. 208 (2014).

2. Board of Regents of the University of Texas System v. Boston Scientific Corporation, 935 F.3d 1367 (Fed. Cir. 2019).

3. eBay Inc. v. MercExchange, L.L.C., 547 U.S. 388 (2006).

4. Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. 66 (2012).

5. U.S. Congress. (2011). Leahy-Smith America Invents Act, Pub. L. No. 112-29, 125 Stat. 284.

6. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.